BioMarin Pharmaceutical

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company's product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.

San Rafael, US
Size (employees)
2,293 (est)+7%
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in San Rafael, Novato, Kronberg im Taunus, Cork and in 26 other locations
San Rafael, US
New York, US
Phoenix, US
Denver, US
New Orleans, US
Nashville, US
Lincoln, US
Dallas, US
Columbus, US
Chicago, US
Washington, US
Santiago de Compostela, ES
Milan, IT
Paris, FR
Buenos Aires, AR
Mexico City, MX
Mocoa, CO
São Paulo, BR

BioMarin Pharmaceutical Metrics

BioMarin Pharmaceutical Summary

Market capitalization

$16 b

Closing share price

BioMarin Pharmaceutical's current market capitalization is $16 b.

BioMarin Pharmaceutical Financials

BioMarin Pharmaceutical's revenue is $1.1 b in FY, 2016
FY, 2013Y, 2014Y, 2015FY, 2016


$548.5 m$751 m$889.9 b$1.1 b

Revenue growth, %


Gross profit

$452.7 m

Operating expense total

$608.8 m


($156 m)

Net Income

($176.4 m)($630.2 m)

Operating cash flow

$388.3 m

BioMarin Pharmaceutical Market Value History

BioMarin Pharmaceutical Job Categories

BioMarin Pharmaceutical News

BioMarin Pharmaceutical Company Life

You may also be interested in